New England Research & Management Inc. decreased its stake in Abbott Laboratories (NYSE:ABT) by 13.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 27,828 shares of the healthcare product maker’s stock after selling 4,398 shares during the quarter. Abbott Laboratories accounts for about 1.6% of New England Research & Management Inc.’s investment portfolio, making the stock its 11th largest holding. New England Research & Management Inc.’s holdings in Abbott Laboratories were worth $2,013,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently added to or reduced their stakes in ABT. Csenge Advisory Group bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $31,000. Signature Estate & Investment Advisors LLC bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at approximately $103,000. Atlantic Trust LLC bought a new position in shares of Abbott Laboratories in the 2nd quarter valued at approximately $104,000. Security National Bank of SO Dak raised its stake in shares of Abbott Laboratories by 72.0% in the 2nd quarter. Security National Bank of SO Dak now owns 2,098 shares of the healthcare product maker’s stock valued at $128,000 after acquiring an additional 878 shares in the last quarter. Finally, Mainstay Capital Management LLC ADV raised its stake in shares of Abbott Laboratories by 1,069.5% in the 2nd quarter. Mainstay Capital Management LLC ADV now owns 4,374 shares of the healthcare product maker’s stock valued at $131,000 after acquiring an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 72.75% of the company’s stock.
A number of research analysts recently weighed in on ABT shares. Cowen raised their price objective on Abbott Laboratories from $72.00 to $86.00 and gave the company an “average” rating in a research note on Friday, October 5th. Zacks Investment Research downgraded Abbott Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Morgan Stanley raised their price objective on Abbott Laboratories from $82.00 to $85.00 and gave the company an “overweight” rating in a research note on Wednesday, January 2nd. Goldman Sachs Group raised Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $78.00 to $81.00 in a research report on Friday, November 30th. Finally, Barclays assumed coverage on Abbott Laboratories in a research report on Monday, October 15th. They issued an “overweight” rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $76.86.
ABT stock traded down $0.35 during trading on Friday, hitting $68.73. The company had a trading volume of 2,044,430 shares, compared to its average volume of 7,140,442. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.42 and a quick ratio of 1.13. The firm has a market cap of $121.96 billion, a price-to-earnings ratio of 27.49, a P/E/G ratio of 1.86 and a beta of 1.24. Abbott Laboratories has a fifty-two week low of $55.58 and a fifty-two week high of $74.92.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 17th. The healthcare product maker reported $0.75 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.75. Abbott Laboratories had a return on equity of 16.05% and a net margin of 2.91%. The business had revenue of $7.66 billion for the quarter, compared to analyst estimates of $7.65 billion. During the same quarter in the previous year, the firm earned $0.66 EPS. Abbott Laboratories’s quarterly revenue was up 12.1% on a year-over-year basis. On average, research analysts anticipate that Abbott Laboratories will post 2.89 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be given a $0.32 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.28. The ex-dividend date of this dividend is Monday, January 14th. This represents a $1.28 annualized dividend and a yield of 1.86%. Abbott Laboratories’s payout ratio is presently 44.80%.
Abbott Laboratories Company Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.